EP Patent

EP3248600A1 — Combinations and modes of administration of therapeutic agents and combination therapy

Assigned to Abraxis Bioscience LLC · Expires 2017-11-29 · 8y expired

What this patent protects

The present invention provides methods of combination therapy for treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may in…

USPTO Abstract

The present invention provides methods of combination therapy for treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a taxane in a nanoparticle composition based on a metronomic dosing regime.

Drugs covered by this patent

Patent Metadata

Patent number
EP3248600A1
Jurisdiction
EP
Classification
Expires
2017-11-29
Drug substance claim
No
Drug product claim
No
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.